Cargando…
Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline
Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 29...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529405/ https://www.ncbi.nlm.nih.gov/pubmed/34866070 http://dx.doi.org/10.5551/jat.63262 |
_version_ | 1784801485520896000 |
---|---|
author | Matsuoka, Satoshi Kaneko, Hidehiro Kamon, Tatsuya Suzuki, Yuta Yano, Yuichiro Okada, Akira Itoh, Hidetaka Morita, Kojiro Fukui, Akira Fujiu, Katsuhito Michihata, Nobuaki Jo, Taisuke Takeda, Norifumi Morita, Hiroyuki Nakamura, Sunao Yokoo, Takashi Nishiyama, Akira Node, Koichi Yasunaga, Hideo Komuro, Issei |
author_facet | Matsuoka, Satoshi Kaneko, Hidehiro Kamon, Tatsuya Suzuki, Yuta Yano, Yuichiro Okada, Akira Itoh, Hidetaka Morita, Kojiro Fukui, Akira Fujiu, Katsuhito Michihata, Nobuaki Jo, Taisuke Takeda, Norifumi Morita, Hiroyuki Nakamura, Sunao Yokoo, Takashi Nishiyama, Akira Node, Koichi Yasunaga, Hideo Komuro, Issei |
author_sort | Matsuoka, Satoshi |
collection | PubMed |
description | Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 291,522 participants without a history of CVD and not taking any BP-lowering medications from the JMDC Claims Database. RA was defined as Keith–Wagener–Barker system grade ≥ 1. Each participant was classified into one of the six groups: (1) normal or elevated BP without RA, (2) normal or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. Results: Median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. During a mean follow-up of 1,223±830 days, 527 myocardial infarction (MI), 5,718 angina pectoris, 2,890 stroke, and 5,375 heart failure (HF) events occurred. Multivariable Cox regression analyses revealed that the risk of CVD increased with BP category, and this association was pronounced by the presence of RA. Compared with normal or elevated BP without RA, the hazard ratios (HRs) for MI (HR 1.17, 95% CI 0.93–1.47) were higher in stage 1 hypertension without RA. The HRs for MI further increased in stage 1 hypertension with RA (1.86 [1.17–2.95]). This association was present in stroke and HF. Conclusion: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension. |
format | Online Article Text |
id | pubmed-9529405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japan Atherosclerosis Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-95294052022-10-18 Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline Matsuoka, Satoshi Kaneko, Hidehiro Kamon, Tatsuya Suzuki, Yuta Yano, Yuichiro Okada, Akira Itoh, Hidetaka Morita, Kojiro Fukui, Akira Fujiu, Katsuhito Michihata, Nobuaki Jo, Taisuke Takeda, Norifumi Morita, Hiroyuki Nakamura, Sunao Yokoo, Takashi Nishiyama, Akira Node, Koichi Yasunaga, Hideo Komuro, Issei J Atheroscler Thromb Original Article Aim: We investigated whether retinal arteriolosclerosis (RA) could be used for cardiovascular disease (CVD) risk stratification of individuals categorized according to the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) Blood Pressure (BP) guideline. Methods: We studied 291,522 participants without a history of CVD and not taking any BP-lowering medications from the JMDC Claims Database. RA was defined as Keith–Wagener–Barker system grade ≥ 1. Each participant was classified into one of the six groups: (1) normal or elevated BP without RA, (2) normal or elevated BP with RA, (3) stage 1 hypertension without RA, (4) stage 1 hypertension with RA, (5) stage 2 hypertension without RA, and (6) stage 2 hypertension with RA. Results: Median (interquartile range) age was 46 (40–53) years, and 141,397 (48.5%) of the participants were men. During a mean follow-up of 1,223±830 days, 527 myocardial infarction (MI), 5,718 angina pectoris, 2,890 stroke, and 5,375 heart failure (HF) events occurred. Multivariable Cox regression analyses revealed that the risk of CVD increased with BP category, and this association was pronounced by the presence of RA. Compared with normal or elevated BP without RA, the hazard ratios (HRs) for MI (HR 1.17, 95% CI 0.93–1.47) were higher in stage 1 hypertension without RA. The HRs for MI further increased in stage 1 hypertension with RA (1.86 [1.17–2.95]). This association was present in stroke and HF. Conclusion: Incorporation of the assessment for RA may facilitate the CVD risk stratification of people classified based on the 2017 ACC/AHA BP guideline, particularly for those categorized in stage 1 hypertension. Japan Atherosclerosis Society 2022-10-01 2021-12-04 /pmc/articles/PMC9529405/ /pubmed/34866070 http://dx.doi.org/10.5551/jat.63262 Text en 2022 Japan Atherosclerosis Society https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Original Article Matsuoka, Satoshi Kaneko, Hidehiro Kamon, Tatsuya Suzuki, Yuta Yano, Yuichiro Okada, Akira Itoh, Hidetaka Morita, Kojiro Fukui, Akira Fujiu, Katsuhito Michihata, Nobuaki Jo, Taisuke Takeda, Norifumi Morita, Hiroyuki Nakamura, Sunao Yokoo, Takashi Nishiyama, Akira Node, Koichi Yasunaga, Hideo Komuro, Issei Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title | Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title_full | Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title_fullStr | Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title_full_unstemmed | Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title_short | Incorporation of Retinal Arteriolosclerosis into Risk Stratification of Blood Pressure Category According to the 2017 ACC/AHA Blood Pressure Guideline |
title_sort | incorporation of retinal arteriolosclerosis into risk stratification of blood pressure category according to the 2017 acc/aha blood pressure guideline |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529405/ https://www.ncbi.nlm.nih.gov/pubmed/34866070 http://dx.doi.org/10.5551/jat.63262 |
work_keys_str_mv | AT matsuokasatoshi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT kanekohidehiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT kamontatsuya incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT suzukiyuta incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT yanoyuichiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT okadaakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT itohhidetaka incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT moritakojiro incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT fukuiakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT fujiukatsuhito incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT michihatanobuaki incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT jotaisuke incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT takedanorifumi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT moritahiroyuki incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT nakamurasunao incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT yokootakashi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT nishiyamaakira incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT nodekoichi incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT yasunagahideo incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline AT komuroissei incorporationofretinalarteriolosclerosisintoriskstratificationofbloodpressurecategoryaccordingtothe2017accahabloodpressureguideline |